Elon Musk says he’d prefer to lose money to maintain free speech than be censored: ‘The right moral decision’ – Page Six

CANNES Elon Musk said he would prefer X to lose advertising dollars and maintain freedom of speech than have the platform be censored.

There were some advertisers who were insisting on censorship, and at the end of the day if I have to make the choice censorship and money or free speech and losing money were going to pick the second, Musk told WPP CEO Mark Read during his Cannes Lions conversation Wednesday morning.

Were going to support free speech broadly then agree to be censored for money, which is, I think, the right moral decision.

The SpaceX founder made the admission after Read asked Musk, 52, why he told advertisers to go fk ourselves. Although Musk somewhat backtracked on his comment, insisting he wasnt directing it at advertisers as whole, he doubled down on disagreeing with brands who believe there can be no content that they disagree with on the platform.

Theres an important distinction here that we dont want to take money to censor broadly on the platform, the Tesla founder explained. I think that would be wrong.

Musk clarified that he didnt believe free speech meant people could say illegal things and reiterated the importance of free speech within the bounds of the law.

Start your day with Page Six Daily.

The brains behind Neuralink also expressed concern about artificial intelligence causing a crisis of meaning for people as they realize the technology will outperform them.

If the AI can do everything that you can do but better then what is the point of doing things? I think there will be an existential crisis of why do anything? the father of 11 pondered.

I think were at the most interesting time in history.

Read the original:

Elon Musk says he'd prefer to lose money to maintain free speech than be censored: 'The right moral decision' - Page Six

Elon Musk’s Neuralink forced a pregnant employee to work with herpes-infected monkeys that scratched her, lawsuit says – Fortune

Elon Musks brain-implant startup Neuralink Corp. forced an employee to work with monkeys that carried the Herpes B virus in conditions in which the animals scratched her bare skin, according to a complaint filed Friday in state court in California.

The employee, Lindsay Short, said that once she transferred to the companys Fremont, California, site in August 2022, she encountered a work environment fraught with blame, shame, and impossible deadlines. She said she was later fired after telling her supervisors that she was pregnant.

Short sued the company for retaliation, wrongful termination and discrimination based on her gender among other issues.

Neuralink didnt immediately respond to a request for comment on the suit.

The startup is in the early stages of clinical trials for its device, which is aimed at restoring function for paralyzed patients. An Arizona man, Noland Arbaugh, recently underwent surgery and becamethe first human patientto have the device implanted. A quadriplegic, Arbaugh can now successfully play video games by using only his thoughts.

The company has alsocome under firefor the mistreatment of monkeys and other animals in the past, including botched surgeries when it conducted research on monkeys housed at the University of California at Davis. It has since moved monkey research to its own facilities.

Short said she was working with monkeys that carried the Herpes B virus when she was scratched through a glove. She accused the company of failing to provide proper protective gear to work with the monkeys. In another incident, after she was forced to perform a procedure she wasnt familiar with, a monkey scratched her face. When she insisted on medical treatment, her boss threatened severe repercussions if it happened again, according to the complaint.

In the lawsuit, Short also said Neuralink didnt honor a promise for flexible work hours to accommodate her family, then demoted her in May 2023, two months after a promotion.

The following month, she told Neuralinks human resources department she was pregnant. Short was fired the following day with the company saying the dismissal was for performance issues, according to the lawsuit.

More:

Elon Musk's Neuralink forced a pregnant employee to work with herpes-infected monkeys that scratched her, lawsuit says - Fortune

Elon Musk says he is working on ‘Tesla Master Plan Part 4’ – Electrek.co

Elon Musk claims he is working on Tesla Master Plan Part 4 a second part of the on going master plan in as many years.

Part One and Two of Musks master plan for Tesla have been important pieces of literature at the company that, in many ways, laid the path to its success.

Tesla has achieved most of the goals listed in its first two master plans.

Last year, Musk released his Master Plan Part 3 through a presentation and a white paper. The third part was quite different from the first two. It didnt really push any specific product roadmap, like the first two, and instead focused on doing the math on how we can move the entire world to a sustainable economy through electric vehicles and renewable energy.

Now, the CEO says that he is already working on a Tesla Master Plan 4:

And apparently, it is going to be epic.

On August 2, 2006, Musk published a blog post titledThe Secret Tesla Motors Master Plan (just between you and me).

The post is worth a read, but it ends in a summary with the core principle being laid out in four steps:

It didnt happen smoothly, but Tesla managed that for the most part with the Roadster, Model S, and then Model 3.

In 2016, Musk followed up with theTesla Master Plan Part 2.

Part 2 came as Tesla was delivering the Model 3 and acquiring Solar City, which are basically the last two steps of the original plans.

In Part 2, Musk emphasized the integration of energy storage with renewable energy generation under the new Tesla Energy division. The creation of the solar roof was also announced in the plan.

The updated plan was also focused on self-driving capabilities, which became a priority at Tesla.

Musk summarized the Master Plan Part 2 at the end:

Among the other segments mentioned in the plan, Musk mentioned a new kind of pickup, which ended up being the Cybertruck; a compact SUV, the Model Y; a heavy-duty truck, which became the Tesla Semi; and finally high passenger-density urban transport.

Every vehicle announced in the plan was unveiled, and most of them are in production, except for the high passenger-density urban transport.

I feel like the Tesla master plans dont hold as much value now that Elon has clearly shifted Tesla to an AI company.

The Part 3 was all about scaling the auto and energy businesses at a scale that would accelerate the entire economys transition to sustainability.

However, in the last few months, Elon killed, or at least indefinitely postponed, the $25,000 Tesla on the unboxed platform, which was a major part of the master plan part 3.

With part 3 and some of part 2 not completed, it feels premature to jump to part 4, but Im pretty confident it is going to be all about self-driving and robots.

FTC: We use income earning auto affiliate links. More.

The rest is here:

Elon Musk says he is working on 'Tesla Master Plan Part 4' - Electrek.co

Linda Yaccarino shares her biggest moment of imposter syndrome from her last year running Elon Musk’s X – Fortune

The moment that most made Linda Yaccarino doubt that she belonged in her role as X CEOand ultimately helped her shed the nagging worryoccurred at January Senate hearings into child exploitation on social media platforms.

It was one of the most pivotal moments not just of last year but of my entire life, Yaccarino said Monday in a conversation with Shelley Zalis, founder and CEO of the Female Quotient, at this weeks Cannes Lions, the advertising worlds version of the Oscars.

Going into the hearings, Yaccarino said, she had only been at the company six months and therefore lacked what she called the depth of knowledge and tenure enjoyed by the four male counterparts from the likes of Meta and TikTok sitting beside her on the panel.

Im not an engineer, Im not a founder, and my natural kind of career-long upbringing was not in tech and social media, she said, describing a feeling of not belonging commonly known as Imposter Syndrome. And by the way, [I was] the only woman.

Yaccarino said she had been keen to share the work undertaken by X on her watch to better protect children on the platform, but worried she would be able to do so with confidence.

Ultimately, she says, what helped her do so was the preparation process, the data she had to back up her assertions, and the encouragement and support she received from the company.

That fueled me and fueled my confidence to be successful that day, said Yaccarino, who has regularly faced criticism shes apuppet CEOor really a glorified COO put in place to implement Musks ordersor has been set up by Musk totake the fallshould the company fail.

When asked by Zalis to highlight an example or two of the relationship she enjoys with Musk, Yaccarino cited the day the entrepreneur announced in May that he had hired a female CEO to run Twitter.

I think that was the best message I ever got of all time, she added.

At the time, Yaccarino and Musk had been discussing his vision of moving away from Twitter as a 140-character messaging service. Instead, it would pivot toward avideo-first platformofferingaudio callsandsoononline payments, allunder the banner of championingfree speech.

The scope of our ambition and the pace of the innovation at the company is like nothing I can describe to any of you. Its exhilarating, slightly exhausting, but it is an opportunity of a lifetime to watch it happening, said Yaccarino.

Counter to what many critics expected and indeed Musks own worst fears, X hasnot gone bankruptsince Musk wasforcedunder penalty of court tohonor in fullhis contract to buy Twitter for $44 billion.

Its survived a period when itreportedly refused to paycountlessbills, witnessed the proliferation ofimposter accounts,and eliminated the majority of its headcount (including even themost dedicated).

Yaccarino even managed to steer the company ahead after Musk told former advertisers like Disney to go f*** yourself, adding on Monday that in retrospect shed have taken the job again in a heartbeat.

But the transition into a more lucrative video-first platform has been slow despite every attempt by Musk to stream his Diablo IV video gaming live to followers.

When Musk urged popular Twitch streamers to switch to X by attacking his Amazon-owned rival for its failure to police its content, he waspromptly ridiculedover his own platformsinfestation of bots.

Days later, X announced its own change of courseand reworded its terms of service to specifically permit sharing content not safe for work. It subsequentlyeliminated any ability to see what posts users like.

In other words, Yaccarino and her team still have a lot of work to do if X is indeed to become theeverything app. Right now users only spend some 35 minutes a day on the platform, according to Yaccarino. While she believes that will only go up going forward once payments are rolled out starting in the U.S. market, that number is still far from the declared goal of users spending, in her words, most of their lives on the platform.

But her experience testifying alongside four peers on the issue of policing child grooming and sexual exploitation on social media helped boost her confidence to succeed in this task as well.Interviewer Zalis of the Female Quotient was quick to agree: If you actually watch the hearing, it was Linda and five [sic] dudesand she smoked em.

Here is the original post:

Linda Yaccarino shares her biggest moment of imposter syndrome from her last year running Elon Musk's X - Fortune

Elon Musk says Tesla will give some new stock options to top performers – Electrek.co

Elon Musk says Tesla will give some new stock options to top performers after shareholders approved his own record-breaking compensation package.

Part of the irony behind the fact that a judge rescinded Musks CEO compensation package at Tesla for misleading shareholders is the fact that the weeks prior to the decision, Tesla had also canceled stock compensations for employees.

However, employees didnt have shareholders rallying to make sure they get their stock options like Musk had.

Last week, shareholders voted again for Musk to get his compensation plan worth $55 billion in shares.

Following his victory at the shareholders meeting, Musk now says that Tesla will again start giving out stock options to employees, but not to everyone.

The CEO now says that grants will go to exceptional performance:

Over the next few weeks, Tesla will be doing a comprehensive review to provide stock option grants for exceptional performance. There will also be an ongoing program to award spot option grants for anyone who does something outstanding for the company. Thanks for everything youre doing to make Tesla successful.

On top of canceling stock options for employees at the end of last year, Tesla also canceled pay adjustments for many workers.

Musk has often used Teslas stock options, which were available to all employees, to argue that Tesla pays its workers better than most other automakers.

That was true when Teslas stock performed well, but the stock is down 26% year-to-date.

I really wish shareholders would have fought for employees to keep their stock options half as much as they did for Elon.

Now, it looks like Elon felt bad that he is getting his stock options, as long as a judge agrees with Teslas use of ratification, but Tesla employees werent.

Not bad enough to give them back to all workers, but only to do those with exceptional performance. I guess thats a start.

FTC: We use income earning auto affiliate links. More.

View original post here:

Elon Musk says Tesla will give some new stock options to top performers - Electrek.co

Elon Musk wants X to compete with Venmo on payments – Quartz

Illustration : Dan Kitwood ( Getty Images )

Elon Musk wants to turn X into an everything app including a place to store, send, and spend money, according to documents made public by Bloomberg.

Nvidia's hot streak is real, but the AI bubble will come, strategist says

The documents, which were submitted to state regulators by the company and obtained by Bloomberg Businessweek through public-records requests, show X plans to have a Venmo-like feature where users can store money, pay other users or businesses, and shop at physical stores with their account. The documents also show X doesnt plan to charge users significant fees for the service. X has told regulators the payment service could lead to increased participation and engagement on the app, which would in turn improve business.

X will reportedly give users access to a dashboard showing payments activities. The dashboard will also be where users can send, receive, and store money on their X account. A plan submitted to Massachusetts regulators shows X plans to charge users small fees for some transactions, but that Twitter Payments does not anticipate charging fees for all of its Services, as the overall goal of the Services is to help increase participation and engagement on the X Platform, according to Bloomberg.

According to X, a wholly owned subsidiary of X called X Payments is licensed to transmit money in 28 states. X wants licenses in all 50 states, and aims to launch X Payments later this year, Bloomberg reported, adding that emails show it is expecting a multi-year process to get the licenses. The company reportedly wanted to launch X Payments internationally this year, but received regulatory pushback and paused its efforts.

In April, Musk said new users to the platform would have to pay a small fee to post, because it is the only way to curb the relentless onslaught of bots. It is also likely an effort by the company to make money as it loses value under Musks leadership.

Read the rest here:

Elon Musk wants X to compete with Venmo on payments - Quartz

Elon Musk Confirms a Massive Super Micro Computer Server Win – 24/7 Wall St.

Investing

Published: June 19, 2024 5:00 pm

Markets were closed on Wednesday, but that didnt stop Elon Musk from breaking some news that could be very material for Super Micro Computer (Nasdaq: SMCI) shareholders. On X, the platform he acquired in 2022, Musk seemed to confirm that Super Micro will be splitting a win for servers with Dell that are going to his AI company, xAI. Lets look at the details.

On Wednesday morning Michael Dell posted a tweet that showed dozens of servers readying for shipment.

Recently, there has been some controversy as e-mails were obtained by CNBC that showed Elon Musk asking NVIDIA to prioritize shipments of AI processors to both X and xAI ahead of Tesla.

xAI also raised $6 billion in Series B funding in May at a $24 billion valuation. Those funds were raised to build the companys infrastructure and accelerate research and development. So, its unsurprising that the company is looking to use the fresh capital to invest in its data centers.

However, shortly after Dells tweet Elon Musk clarified that Dell would only be building half the racks going into the supercomputer xAI is building. In a follow-up Tweet, he seemed to confirm the other half would go to Super Micro Computer.

Source: gorodenkoff / iStock via Getty Images

Super Micros stock has been on a winning streak across the past week, up 17% in the past five days. A large win with a customer like xAI trickling out could explain some recent enthusiasm.

While Super Micro continues to see sales skyrocket, the company has been under recent pressure. Dells (NYSE: DELL) last quarterly report led to widespread commentary that AI server sales werent seeing higher margins than traditional servers. A key thesis surrounding server companies is that they can raise margins thanks to added complexity in AI servers.

Another pressure point has come from NVIDIA (Nasdaq: NVDA). The company is reportedly pushing large companies like Microsoft to buy their GB200 server racks exactly as designed by NVIDIA. If NVIDIA continues pushing further into server designs, this would move into the territory occupied by Super Micro and Dell.

Musk is known for claims that can be excessive but has claimed the newest model (Grok 3) from xAI could require 100,000 H100 chips from NVIDIA. That could lead to even more fundraising. Wall Street is expecting Supr Micro to book $14.9 billion in sales in 2024 and $23.6 billion next year, so a company with $6 billion in funding (and the possibility to raise more) largely earmarked for procuring computing power could be a very material win.

If you want your portfolio to pay you cash like clockwork, its time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.

Theres a better option, and we want to show you. Were offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.

If youre tired of feeling one step behind in this market, this free report is a must-read for you.

Thank you for reading! Have some feedback for us? Contact the 24/7 Wall St. editorial team.

Read more:

Elon Musk Confirms a Massive Super Micro Computer Server Win - 24/7 Wall St.

Tesla CEO Elon Musk announces Robotaxi unveil date: ‘The vehicle is going to result in a cost per mile cheaper than a … – Yahoo Autos

Tesla delivered over 386,000 electric vehicles in Q1 (January-March) 2024, according to Business Wire. Now, the company is turning its focus to the next innovation: the Robotaxi.

In a post on X, formerly known as Twitter, Tesla CEO Elon Musk (@elonmusk) announced the new unveil date for the Robotaxi: August 8, 2024.

Tesla Robotaxi unveil on 8/8

Elon Musk (@elonmusk) April 5, 2024

Musk originally predicted Robotaxis could be available in 2020, when he announced it at an "autonomous day" event for Tesla in 2019. After missing that deadline, the CEO pushed for a new timeline.

"We aspire to reach volume production in 2024," Musk said, according to ZDNet. "Especially with the Robotaxi and autonomy, I think we'll end up providing consumers with by far the lowest cost-per-mile transport that they've ever experienced."

According to Electrek, Musk believes that "the vehicle is going to result in a cost per mile cheaper than a subsidized bus ticket." While the cost of a bus differs depending on the metro area, the cost per mile can range from $7.40 in Charlotte to $30.40 in New York City, as reported by Curbed.

Teslarati reports that the Robotaxi could have two designs: a $25,000 car that would be cheaper than current models on the market, which consumers can drive, and a second model that comes without a steering wheel and is built to be fully autonomous.

These models could come with two new features, Teslarati reports: a rider quality score much like driver/rider ratings for Uber/Lyft and a guest mode. The guest mode could be similar to valet mode, a feature that is available in current Tesla models that reduces max speed and acceleration for added security and safety.

Autonomous cars could have several benefits.

Story continues

They could lead to fewer injuries and deaths. Car crashes are the leading cause of death in the U.S. for those aged between 1 and 54, according to USA Today.

They can also reduce congestion, which would shorten commute times. Less congestion would also reduce environmental problems, as idle cars increase global temperatures, which causes more extreme weather events. And it doesn't have to stop at cars this company found success with self-driving tractors.

However, there are reports of self-driving cars being unsafe, and Tesla had to recall models last year. Tesla looks to continually progress with safety measures, as it has for the Cybertruck. The company even received a safety award for the Tesla Model Y.

The unveiling of the Robotaxi in August could provide us with more details on a timeline for this new technology and added safety measures.

"I am totally convinced that complete self driving will be a reality much sooner than most people believe," one user commented.

Other commenters were excited about the prospect of safety.

"Robotaxi is definitely the future calling, in so many ways," commented one user. "New platform. Can even be used as public transport shuttle by cities. No more crashes from over speeding, drunk driving, sleepy drivers, jumping signal."

Join our free newsletter for cool news and actionable info that makes it easy to help yourself while helping the planet.

Read the original post:

Tesla CEO Elon Musk announces Robotaxi unveil date: 'The vehicle is going to result in a cost per mile cheaper than a ... - Yahoo Autos

Neurological conditions claim the lives of thousands of children every year. New treatments in the womb may save them – BBC.com

Cutting-edge therapies delivering treatment to foetuses diagnosed with neurological defects have the potential to change natal care as we know it.

Michelle Johnsons fourth pregnancy was all going according to plan until the specialist giving her the standard 20-week ultrasound stiffened slightly while prodding her belly. The ultrasonographer got "really awkward" and was erratically asking questions, Johnson recalls, like if they already had kids. Several days later, the departments head radiologist called. His tone was sombre as he fumbled for words and said that it was rare in his experience, but Johnson needed to see a gestational foetal medicine specialist immediately because her child had spina bifida.

Known to science as myelomeningocele, spina bifida is when the spinal cord which starts developing in children as a cannoli-shaped tube, folding onto itself to encapsulate the nervous system doesn't fully fuse close. It leaves the superhighway of nerves to spill into a small bulge somewhere along the spine. This nervous system birth defect can lead to lifelong cognitive issues as well as chronically impaired mobility and paralysis from the hips down.

"It was just devastating," says Johnson, who was 35 years old at the time and living in Portland, Oregon, US. "I was just in shock."

Each year around 1,400 babies are born in the US with spina bifida. The exact cause of this complex condition is not known, but it is thought to involve a combination of genetic and environmental factors. Low levels of folic acid intake during pregnancy or certain anti-seizure medications, for example, have been associated with a higher risk of the condition, but it is not clear how great a role these play.

Spina bifida is customarily treated in the 24 to 48 hours immediately following childbirth: surgeons sew up the spinal cord and tuck it back into the baby's body, preventing the condition from degenerating any further. But while making calls for appointments with a specialist, a nurse on the phone told Johnson about a new programme in California that uses stem cells to treat children with spina bifida while they are still in the womb.

If she chose to be involved, her baby would be the second human patient to ever undergo this type of treatment. Johnson knew it was a chance she wanted to give her unborn child.

Since the procedure had to happen before the 26th week of pregnancy, "it was like a race", says Johnson. Several scans, blood tests, and interviews later, she embarked on something larger than life.

Prenatal screening for neurological conditions has progressed in leaps and bounds over the past couple of decades. Technology including genetic analysis, neuroimaging, and high-resolution foetal magnetic resonance imaging (MRI) are allowing doctors to peer into the nervous systems of developing foetuses and already diagnose them earlier and more frequently with any life-altering conditions they'll experience once born. But throughout this advancement, there hasn't been much doctors could do about those diagnoses until the child emerged from the womb. And a significant portion of crucial brain development happens long before a child is born.

Now, a new wave of pioneering in-utero neuroscience therapies are helping to change that. Several seminal trials are underway to test both surgical and medical treatments allowing doctors to reverse conditions in babies before they are born. And the field is "right on the precipice" of a whole new dimension of therapies, says Jeffrey Russ, a pediatric neurologist at Duke University who recently wrote an academic essay describing in-utero treatment as the "next frontier" in neurology.

One of these frontier treatments is the current first Food and Drug Administration (FDA) approved clinical trial treating spina bifida in utero with placental stem cells. The project, known as the CuRe Trial, is the culmination of 25 years of work of foetal surgeon Diana Lee Farmer, from the University of California, Davis.

In-utero operations where the spinal cord opening is sewn shut have become standard care for cases of very severe spina bifida. They slow the degeneration of the disease throughout the pregnancy and improve patient outcomes more than post-birth surgeries, as years of work by Farmer suggest . But her new project aims to take it a step further. By mending the open neural tube with a patch seeded with stem cells from bits of the mother's placenta known as "mesenchymal stromal cells", derived and cultured in a painstakingly precise four-day process the cells should actively go in and reverse the damage that has already occurred by the time of diagnosis.

These stem cells "are very smart", says Aijun Wang, the bioengineer who developed this stem cell technology for the CuRe trial. "They can protect neurons from being killed by the environment."

Preliminary data from running this experiment on lambs with spina bifida suggested the treatment allowed them to prance around without any noticeable disability when they would have otherwise been paralysed in their hind legs. The same was observed when the procedure was performed on bulldogs.

More than 30 people were in the operation room when Johnson, just a day shy of the 26-week pregnancy cutoff, became the second human patient to undergo this surgery. An incision was made into her watermelon-shaped belly, the uterus was pulled almost fully out of the body, and the foetus was floated up to the opening in the uterus. This allowed doctors to reach the hernia on the minuscule baby spine, and delicately apply the stem cell patch. The doctors used special microscopes to perform their surgery because the baby was so small.

If the child a boy to be named Tobias had remained untreated, he would have been born with paralysis from the hips down. On 1 February 2022, he was born via caesarian-section at 7lbs 13oz (3.5kg), legs kicking, toes wriggling. "It just feels like we won the lottery," says Johnson.

Tobias will have to be monitored until he turns 30 months old his last in-person visit is upcoming this summer before officially assessing the full safety and efficacy of the procedure, for the sake of the experiment. And doctors will likely continue to follow him until he turns at least five. At the time of writing, 10 more patients have received CuRe treatment, and Farmer's team has secured $15m (12m) of funding for 29 more patients, with the hopes of enrolling about 10 patients a year. It will not be till 2028 that Farmers team will be able to review all of the data collected and confirm whether this new therapy could become standard for children across the country.

"I'm hopeful that we may be able to make a very significant improvement in the outcome of these kids with spina bifida," says Farmer. "But like every good scientific project, you answer one question and that opens the door to another question."

This is cutting-edge science for anatomic conditions that can be surgically repaired, according to Russ. But another frontier where in-utero therapies have the potential to turn the tables of neurological conditions in newborn babies is where therapies can be delivered at a molecular or genetic level. This is a "totally new concept" that will "open a whole new realm", says Russ.

His colleagues at Duke University contributed to the design of a protocol for the first-ever in-utero treatment for Pompe's disease a rare genetic disease that causes cells to hold onto too many complex sugars, leading to neurological conditions, breathing problems, heart issues, and muscle weakness. Most patients die within one or two years of birth.

Since Pompe's is caused by the lack of an enzyme called acid alpha-glucosidase, it's usually treated with enzyme replacement therapy (ERT), where children receive regular injections of the enzyme. Like with spina bifida, though,data has shown that starting ERT as soon as the baby is born can improve symptoms but it cannot fully stop the disease from manifesting.

So, when doctors at The Ottawa Hospital in Ontario, Canada, ran tests on an unborn girl called Ayla Bashir in February 2021, revealing she had inherited the same genes that led two of her siblings, Zara and Sara, to be diagnosed with Pompe's after birth they knew they had to act quickly. Both Zara and Sara had died aged 29 months and eight months, respectively. But with Ayla's in-utero diagnosis, the medical team could intervene sooner.

On March 24, 2021, doctors delivered the first dose of enzyme replacement to Ayla while she was still in her mother's womb at 24 weeks and five days of gestation. They injected into the umbilical vein a liquid formula containing a copy of the missing enzyme called alglucosidase alfa. This approach allows the manufactured enzyme to make its way into the foetus's bloodstream while it is still developing. It means it barely notices the drug as foreign to itself, and doesn't have the strong immune response that can occur during treatment after birth. Six more infusions every two weeks followed. Ayla was born on June 22, 2021, and ever since she has been getting enzyme injections every week.

"Ayla is a very happy, mobile three year old who is meeting all her neurodevelopmental milestones," says Karen Fung-Kee-Fung, the maternal foetal medicine specialist at The Ottawa Hospital who treated her. "[I] just saw a video of her jumping up and down."

Similarly to Tobias, doctors will continue to follow Ayla for at least five years to monitor any disease progression, as the therapy does not completely prevent irreversible organ damage. But Ayla's story paves the way for setting up prenatal medical treatments that intervene in disorders like these with a simple injection.

"We were hoping to change the paradigm for when you can treat a genetic disease," says Tippi Mackenzie, one of the foetal surgeons at the University of California, San Francisco who led the development of the protocol which was used to treat Ayla.

There are several treatments currently offered to newborns that could potentially be offered during the foetal phase, says Mackenzie. She has established an ongoing five-year clinical trial for a total of 10 patients underway in California to help officially establish in-utero ERT as an approved procedure for Pompe's and other rare diseases such as Neuronopathic Gaucher disease, Mucopolysaccharidosis, and Wolman disease. Two babies with Mucopolysaccharidosis were already treated as part of the trial and "updates are positive", says Mackenzie. They are continuing to enroll patients for the trial, which is open for international patients.

Developing a foetal treatment for conditions like these would also help to raise awareness about the need for more testing for genetic diseases in the first place "changing the equation" by allowing a virtuous cycle of more diagnoses and more treatments, says Mackenzie. "The diagnosis and treatment, I call them a yin and yang, they go together," she says.

And while enzyme replacement is the least invasive type of treatment for genetic disorders and requires multiple dosages throughout a patient's lifetime this new method could be adapted to deliver other hotly debated gene therapies for editing an unborn baby's DNA, by either snipping out a defective gene or replacing a missing one.

Mackenzie's work is "laying the foundation for these types of advanced therapies in the future", says William Peranteau, a professor of surgery at the Children's Hospital of Philadelphia. "If those trials can demonstrate a benefit to treating the diseases before birth with an enzyme replacement therapy, then the obvious next question is a more definitive therapy like in-utero gene editing."

When it comes to estimating how long it'll be until gene-editing therapies will get human trials, though, it's always a very difficult question to answer, and "it always takes longer than we want or expect it to", says Peranteau. Maybe five to 10 years. "It's a matter of just doing the work," he says.

For now, as these trials pick up pace, it'll be imperative to consider the ethical and practical implications of these advancements.

"We'll have to start with really specific examples, where it's very clear that the benefits outweigh the risks," says Russ. Obviously, not all conditions can and should be treated with stem cells, enzyme replacement, and gene-editing technology before birth.

And it's still too early to have a clear picture of the long-term effects of these in-utero treatments. Most of the patients from these in-utero trials are still babies or very young children. We also still don't have long-term data from adult patients who are currently undergoing gene editing therapies, either. So while surgeries and chemical therapies like those developed by Farmer and Mackenzie are mostly short-lived procedures, once doctors edit the genetic code of an unborn baby these changes, and their effects, will be forever.

Crucially, in-utero therapies are unique procedures with double the risks and stakes, since they involve the mother as well as her unborn child, says Russ: "You're not just treating one patient, you're treating two."

Johnsons family travelled back to California a little over a year after the procedure. Johnson got to meet other mothers from the CuRe trial, and the hospital staff all took turns coming by, saying hello, and playing with Tobias in the courtyard, bringing him cake and candles to celebrate his first birthday.

"It was really special," says Johnson. "Really full circle for them to see all the work they're doing and to meet this miracle baby and see how healthy and happy he is."

At the time of writing, Tobias is more than two years old, and he has learned to walk.

Read more:
Neurological conditions claim the lives of thousands of children every year. New treatments in the womb may save them - BBC.com

Inherited Alzheimer’s: Whether It’s From Mom or Dad Could Matter – HealthDay

MONDAY, June 17, 2024 (HealthDay News) -- Genetics can play a role in a person's odds for Alzheimer's disease, and new research suggests differences in that risk are based on which parent had the illness.

In a study of 4,400 people still "cognitively unimpaired," there was higher buildup of amyloid protein plaques in the brain (a hallmark of Alzheimer's) if either the person's mother, or both parents, had Alzheimer's, compared to folks where Alzheimer's had only struck the father.

People with an Alzheimer's-affected mother may therefore be at special risk, said a team from Mass General Brigham, in Boston.

"Maternal inheritance of Alzheimers disease may be an important factor in identifying asymptomatic individuals for ongoing and future prevention trials, said study co-author Dr Reisa Sperling, a neurologist at Mass General.

The findings were published June 17 in the journal JAMA Neurology.

The study was based on data from a clinical trial focused on Alzheimer's prevention. People in the study were asked about whether or not either of their parents had ever been diagnosed with Alzheimer's disease, and when their parent's memory began to fail.

Sperling and colleagues then compared those answers to levels of amyloid in people's brains.

Having had a father who developed Alzheimer's symptoms relatively late in life did not seem to be related to levels of amyloid in people's brains, the research showed.

However, there was a correlation between the accumulation of brain plaques and having had a mother whose Alzheimer's symptoms began at any age, or having a father whose symptoms began relatively early, the team reported.

If your father had early-onset symptoms, that is associated with elevated [amyloid] levels in the offspring, said study first author Dr. Mabel Seto, a postdoctoral research fellow in the hospital's department of neurology. However, it doesnt matter when your mother started developing symptoms -- if she did at all, its associated with elevated amyloid.

The sex of the study participant did not seem to matter when it came to the relationship between amyloid buildup and parental histories, the researchers noted.

Its also important to note a majority of these participants are non-Hispanic white, Seto added in a Brigham news release. We might not see the same effect in other races and ethnicities.

More information

Find out more about Alzheimer's disease and genetics at the Alzheimer's Association.

SOURCE: Mass General Brigham, news release, June 15, 2024

More:
Inherited Alzheimer's: Whether It's From Mom or Dad Could Matter - HealthDay

Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing … – PR Newswire

Ascidian to receive $42 million in initial payment, and up to $1.8 billion in research, clinical and commercial milestone payments, as well as commercial royalties

Per-target agreement enables Ascidian to pursue additional internal and collaborative programs within neurology and other therapeutic areas

Combines RNA Exon Editors with next generation CNS delivery capabilities of Roche to develop novel medicines for difficult to treat neurological diseases

BOSTON, June 18, 2024 /PRNewswire/ --Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG;OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.

Ascidian's RNA exon editing platform is designed to advance the therapeutic possibilities of RNA medicine and treat diseases not addressed by today's gene editing technologies. The company designs and develops RNA exon editing therapeutics that edit RNA exons at the kilobase scale.

Under the agreement, Ascidian will provide Roche exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets. Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, and Roche will be responsible for certain preclinical activities, and further clinical development, manufacturing, and commercialization. Ascidian will receive an initial payment of $42 million and is eligible to receive up to $1.8 billion in research, clinical, and commercial milestone payments, as well as royalties on commercial sales worldwide. Based on the terms of the agreement, Ascidian is free to develop programs against other neurological targets internally or with other collaborators.

"Roche is known and respected worldwide for their expertise in complex neurological diseases, and I am proud of the scientific rigor and quality of the work done at Ascidian that has led to this partnership," saidMichael Ehlers,M.D., Ph.D., President and Chief Executive Officer of Ascidian Therapeutics. "The potential of treating disease by large-scale exon editing of RNA is vast. We look forward to working with the Roche team to develop first-in-class RNA exon editing medicines for multiple neurological diseases, with a mission and passion to relieve suffering and improve lives."

"Our partnership with Ascidian is an opportunity to harness advanced RNA exon editing technology, which has the potential to deliver transformative one-time therapeutics by editing multiple whole exons at the RNA level with a single treatment," said James Sabry, M.D., Ph.D., Global Head of Pharma Partnering at Roche.

Ascidian's platform enables targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. By rewriting RNA, Ascidian's exon editing technology is designed to provide the durability of gene therapy, while sharply reducing risks associated with direct DNA editing and gene replacement.

About Ascidian Therapeutics

Ascidian Therapeutics, an ATP company, is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With discovery, preclinical, and clinical programs in retinal, neurological, neuromuscular, and genetically defined diseases, Ascidian's approach has the potential to treat patients with one dose of an RNA exon editor, opening new therapeutic possibilities for patients and their families who are seeking breakthroughs. Earlier this year, Ascidian announced U.S. FDA IND clearance for the first-ever RNA exon editing candidate, ACDN-01, which targets Stargardt disease and other ABCA4 retinopathies. Ascidian is currently executing the Phase 1/2 STELLAR clinical trial to evaluate the safety and efficacy of ACDN-01. For more information, visit http://www.ascidian.com.

SOURCE Ascidian Therapeutics

Link:
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing ... - PR Newswire

Neurology ‘House Calls’ to Improve Quality of Care and Life for ALS Patients – Mega Doctor News

Dr. Keelie Denson, a second-year neurology resident at Houston Methodist, watched first-hand as her father James and family faced ALS from her childhood until his death when she was 13. Image of illustration purposes

Mega Doctor News

ByPattiMuckHouston Methodist

Newswise Robert Amar, a U.S. Army veteran, was diagnosed with Amyotrophic Lateral Sclerosis when he was a fit and healthy 45 years old. Fourteen years later, he has lost his ability to walk, talk, swallow and breathe on his own.

His high school sweetheart Angela, and the couples three adult children Victoria, Robert and Marissa and a few dedicated caregivers are his 24/7 caretakers. Commonly known as Lou Gehrigs disease after the New York Yankees hero of the 1930s, ALS is an incurable disease of the neuromuscular system. The diseases progression and symptoms vary widely from patient to patient, ultimately giving the patient a ringside seat as their bodies melt away, says Dr. Stanley Appel, director of the Johnson Center for Cellular Therapeutics at Houston Methodist and internationally respected ALS expert. He founded the nations first multidisciplinary ALS Clinic at Houston Methodist in 1982.

You hear those three letters A-L-S and it just changes your whole life forever, says Angela, Roberts wife of 29 years. We just love him so much and we would do anything for him.

Robert is among the first Houston Methodist ALS patients enrolled in a research study designed to provide a multidisciplinary standard of care to those whose disease has rendered them homebound.

24 ALS patients enrolled in first-of-its-kind study

Dr. Keelie Denson, a second-year neurology resident at Houston Methodist, watched first-hand as her father James and family faced ALS from her childhood until his death when she was 13. As patients progress in their disease, it becomes harder and harder for them to make it to multidisciplinary care visits in a clinic setting, says Dr. Denson. These are already geographically sparse to begin with.

Eventually, ALS patients and their families can be overwhelmed by the struggle to obtain consistent continuity of care from their team of specialists neurologists, social workers, speech therapists, physical and occupational therapists and dietitians. Worst case scenario? They stop attending clinic and drop off physicians radar.

Were being pulled out at the stage of the disease where our patients are most vulnerable and need us most, says Dr. Denson. There are no studies or resulting data to address this critical need. Until now.

Supported by Dr. Ericka Greene and the multidisciplinary ALS team at Houston Methodist, Dr. Denson designed a study, Caring for the Homebound Patient with ALS, that is following 24 patients and an optional 24 caregivers for 16 months. Patients live within 50 miles of Houston and cant physically visit their neurology team any longer, maybe because theyre too weak and on a ventilator or they dont have transportation, lack access to technology or have financial hardship. For one reason or another, theyve missed one or more clinic visits and are basically on their own in the final stages of their disease.

Half the patients the control group will receive telehealth visits with a neurologist. The other half the intervention group will get quarterly home visits from a neurologist and a social worker, accompanied by a live video conference that includes physical and occupational therapists, a dietitian, a speech therapist, and a medical equipment expert.

Before each visit and at the end of the study, patients and caregivers will complete the gold standard quality of life surveys that will provide data to prove or disprove the theory that multidisciplinary home health care visits improve life for these ALS patients.

If this program meets its endpoints and proves to be feasible, there will be an opportunity to create guidelines and curriculum for other institutions to replicate the program across the nation, Dr. Denson says. Our hope is that this program will become a covered health care service for patients who are homebound because of ALS.

Back to the Basics

Early in the study planning stage, Dr. Denson questioned her ALS families about what they found lacking in ALS care. For the Amar family, the answer was easy: Hands-on care for our loved ones, Angela recalls. As her husbands disease progressed, getting him to the ALS Clinic and other appointments became a monumental struggle. For Robert, leaving home was becoming impossible. It is also very difficult to find caregivers and nurses experienced in caring for someone on a ventilator, feeding tube dependent, non-verbal and paralyzed.

Still, the close-knit family counted their blessings. They were able to celebrate milestones that many ALS families never get to see. Robert met his goal of watching all three children graduate from high school, and then from Texas A&M University. His oldest daughter Victoria hopped on his lap and they did an impromptu wheelchair dance at her wedding. Recently, the first and only grandson Gavin attended his first Houston Astros game at Minute Maid Park and brought his grandfather an Astros T-shirt to Houston Methodist Hospital where Robert was recovering from a recent tracheostomy surgery. A season ticketholder before ALS entered his life, Robert and his family attended Astros World Series games twice. He always made it a point to cheer on his favorite team.

Robert has always been very determined, and he has this positive attitude that Im going to live each day like I always have to the fullest. Angela says.

On the day of his first home visit, Robert was cleaned up, comfortable in his bed, happy and ready to see his team. Five minutes later, complications with his new tracheostomy for breathing, combined with the movement of the morning routine, sent his oxygen levels plummeting. Things can change in a heartbeat, Angela says. Im usually very strong, but I did break down a little bit. It was a very bad day for Robert, but the team got to see the good and the bad. Youre sharing your life with them, and you can see in their faces how concerned they are and how much they care.

Dr. Densons presentation of the ALS home care study generated considerable enthusiasm at an ALS symposium in Switzerland last year, and results will be compiled into a formal report following the 16-month trial.

For more information on Houston Methodists ALS Clinic, visitwww.houstonmethodist.org/ALS-Clinic

This study is possible because of support from The Constance M. and Byron F. Dyer Fellowship and The Lou and Eleanor Gehrig Family Foundation.

Postscript:Robert Amar passed away shortly after his 59thbirthday in mid-May 2024. His life of courage and determination lives on in Kingwood High Schools annual Robert Amar Mental Toughness Award and in his participation in Caring for the Homebound Patient with ALS, the research program outlined in this story designed to help ALS patients now and in the future.

Read more:
Neurology 'House Calls' to Improve Quality of Care and Life for ALS Patients - Mega Doctor News

A neurologist took DIY treatments seriously. Has it sparked a breakthrough? – WHYY

Vitamins, unapproved serums in glass vials, even acupuncture programs. His patients slowly opened up to Bedlack about dozens of supposedly effective elixirs and therapies touted on sketchy websites or anonymous forums that they were trying. The kind of treatments that were easy for physicians to dismiss or ignore.

Really they werent even being recorded, much less talked about like they werent getting into any medical records at the time, said Bedlack. When people were checking in, nurses were only interested in medicines. They werent interested in vitamins and supplements and products that maybe couldnt even be characterized. So, one day I asked, What is all this stuff? and somebody said, well, I figured you probably wouldnt want to talk about this. And then, the more I thought about it, I said, Wow, if this is a common thing that people are doing this, shouldnt I be interested?

His patients simply didnt have time to wait on the conclusions of lengthy clinical trials that might never come for these products and programs. If they were looking elsewhere for answers, Bedlack felt he had a responsibility to weigh in on what they were trying rather than dismiss it all off-hand.

Shouldnt I want to partner with patients using my years of training to try to help them make more informed decisions about these? said Bedlack.

Many of his colleagues in medicine disagreed.

The majority of my peers said, this is a terrible idea because all youre going to do is lend some legitimacy to some of these strange products and websites that are out there. Theyre going to say, you know, this product is under investigation by Dr. Bedlack at Duke and this team of respected scientists, and theyre right. said Bedlack.

But he thought the potential good outweighed the risks.

I just feel like you have to put it all together and ask yourself: How does it all shake out? To me, the need for this in the patient community, the desire for it, far outweighs any of that criticism that I got in the beginning.

In 2009, Bedlack connected a cohort of like-minded researchers to create ALSUntangled a group dedicated to investigating alleged or emerging ALS treatments that spring up online.

What if we work together,? What if we crowdsource this? Like, built a team of clinicians and scientists who were interested in doing this together.

Together, they dug into one of the groups first product reviews: Iplex, a drug that contained a man-made insulin-like growth factor whose dysregulation has long been thought to be involved in ALS. ALSUntangled concluded that data from a seemingly promising Italian study lacked a control group and was potentially tainted with selection bias.

The problem with that is the time that it takes to really investigate one thing. It takes a while, Bedlack said. Ive found that it takes about 40 hours to do a really good investigation of just one product. And, nobody has time, if theres hundreds of these things out there, which there are, nobody has time to do them all.

Since that first review, the ALSUntangled team has grown to over 130 researchers across 11 countries.

Since 2009, there hasnt been a single day that I havent at some point been working on a review of a product that a patient asked about, said Bedlack.

ALSUntangled has reviewed dozens of products and therapies keeping the information up to date whenever new evidence becomes available.

Most have been relatively unremarkable, some pretty dangerous. But a minority have actually shown real promise.

The work has given Bedlack and his team permission to wander down strange paths, just to see where they might lead. And now one of the strangest of paths of them all may finally be paying off.

Two years after publishing that first ALSUntangled review, Bedlack stumbled across yet another seemingly unreliable internet rumor related to ALS.

I came across a video of a woman from Virginia who said that she had ALS, that it was rapidly progressing, that she had lost almost all of her function.

Her name is Nelda Buss a mother of two whose ALS journey began in the mid-80s, when she told her primary care doctor about some foreboding, mysterious symptoms she was experiencing.

It started with my weak hands, said Buss. And then my legs sort of were getting weak. I fell a couple of times. I went back to him and he said, Well, Ill make the neurology appointment like in January.

Buss believed her doctor didnt want to be the one to give her the bad news. She was officially diagnosed with ALS when she was 47. By then she was having difficulty walking.

My husband got up, came up and picked me up. And I think we cried all the way home.

Buss consulted with ALS experts some of the best in the business at the time, according to Rick Bedlack. But she just kept getting worse.

I was diagnosed in January and by July I was in a wheelchair, said Buss.

Desperate, she sought help from Dean Kraft, a man from New York City who claimed to be an energy healer. She had heard about him from a magazine article.

The first time I went to him he gave me the first treatment and my diaphragm was beginning to weaken and I couldnt breathe as well as I could before, Buss told the hosts of the daytime talk show The View back in 1998. And I noticed I could cough and blow my nose better.

Every other week for over a year, Buss and her husband would drive up to New York City from their home in Virginia, where she was carried into Dean Krafts small office. Kraft would place his hands above Buss head and claim to release healing energy.

He would work like two hours on Saturday on me and two hours on Sunday. said Buss.

In total, Buss said she paid Kraft about $25,000 for these sessions.

He said, you just cant always believe the doctors, said Buss.

The first time I went to him he gave me the first treatment and my diaphragm was beginning to weaken and I couldnt breathe as well as I could before, Buss told the hosts of the daytime talk show The View back in 1998. And I noticed I could cough and blow my nose better.

Every other week for over a year, Buss and her husband would drive up to New York City from their home in Virginia, where she was carried into Dean Krafts small office. Kraft would place his hands above Buss head and claim to release healing energy.

He would work like two hours on Saturday on me and two hours on Sunday. said Buss.

In total, Buss said she paid Kraft about $25,000 for these sessions.

He said, you just cant always believe the doctors, said Buss.

Dean Kraft died in 2013 of a massive heart attack. He was 63. Kraft was also featured in the same segment from the View and other videos about Buss story.

I dont require people to believe in religion, he told the hosts. They dont even have to believe in me. I just lay my hands on them and fortunately the majority of people get well.

And after a couple of years, Buss said thats what happened to her.

I had a walking party at the Marriott hotel and invited all our friends, so I had Dean come to the party. So they came down from New York and he wanted me to dance with him.

Rick Bedlack was shocked when he came across the story of Nelda Buss.

She completely recovered and in fact the video was pretty convincing, said Bedlack.

Again, the doctors curiosity kicked in. He contacted Buss and asked if she would give permission for her doctors to send Bedlack her medical records.

She obliged.

By the time I finished those, I was absolutely convinced that she really did have ALS, that she progressed to where she was nearly dead, and then she made a full recovery over the next two years under the care of this energy healer, said Bedlack. What I wasnt convinced of is that it was the energy healing that made her better, in part because it had no plausible mechanism. Like, there is no known biological mechanism where a person can have energy come out of their hands that heals the body dying motor neurons. And so I didnt understand that part.

Bedlack reached out to Kraft to try to organize a study of his methods.

[I] said,I dont know how it is that this happened, but Id like to do a small study of your technique and about 10 more patients. And Ill never forget his response. He said, Richard, for those who believe no more proof is necessary. And for those who dont, no proof is ever going to be enough. And thats the last I ever heard of him.

But the story started a conversation within ALSUntangled about other inexplicable disease reversals his fellow researchers had seen.

They said, did you know these kinds of cases have actually been reported in the literature since the 1960s? And in fact, many of the people on the ALSUntangled team had said, well, you know, I saw somebody that I thought had ALS and they progressed for a while and then they recovered.

His colleagues said they just thought those patients had been misdiagnosed that they didnt really have ALS. But for Bedlack, this was a light bulb moment.

And I was like, Wait a second. How are we not studying these people? How many of them are there? I mean, theres a precedent for studying people who are unexpectedly resistant to diseases and finding pathways that have never been manipulated and finding treatments to manipulate those pathways that wind up helping everyone. said Bedlack.

So Bedlack started yet another program to study these reversal cases. He began digging out medical records, sending out questionnaires, and trying to find commonalities.

Suddenly Im in a whole other direction for the past 12, 13 years, this whole ALS reversals research. But I have to say thats also gotten quite interesting.

Bedlack has confirmed 22 other ALS reversals. And just last year, his searching spawned a breakthrough.

We actually found a target, said Bedlack. About a third of these patients appear to have a genetic abnormality thats very, very rare in people with typically progressive ALS. I think thats the most likely explanation for at least a third of these ALS reversals. And we are now doing a much larger study to see in a huge population of people with ALS: is there a relationship? If there is a relationship, I will be dropping just about everything and engaging in a clinical trial. But again, here I am in a space in a direction that I never thought I would be.

Nelda Buss is now 82 years old and she still believes Dean Kraft saved her life. But she remains open to other explanations, assuming Rick Bedlack and his tireless team of researchers can find one.

Go here to see the original:
A neurologist took DIY treatments seriously. Has it sparked a breakthrough? - WHYY

Neurology residents offering virtual field trip into the brain – University of Nebraska Medical Center

A group of UNMC neurology residents are offering Nebraska students a field trip into the human brain.

For the Nebraska 4-H programs virtual field trips series, residents Isha Snehal, MBBS, Kanchan Kumari, MD, and Zaid Najdawi, MD, worked with the University of Nebraska-Lincolns Nebraska Extension to create a video on brain issues around epilepsy, stroke and concussions.

The series is geared toward Nebraska high school students and originally was established during the pandemic to offer engaging virtual experiences in STEM and ag-related fields, said Sarah Paisley, an associate educator with Nebraska Extension based out of Garden and Morrill Counties.

The program reached out to the UNMC Department of Neurological Sciences, hoping to show the complexity of the brain and what happens after a trauma.

Click Play below to see the video titled, Neurology Whats Going on with My Brain?

Dr. Snehal said awareness of strokes, epilepsy and concussions is important because of the large number of people they affect. Not only have many high school students heard or experienced those issues in different ways, they also could learn how to help if those problems happen around them, she said.

The hope is that the outreach can educate and create awareness about these issues among as many kids as possible, Dr. Snehal said, and they can use some of the tips when they do find themselves in a situation to help others.

Paisley said the video also highlights some great neurological studies going on right here in Nebraska at UNMC.

If students are interested in health care as a career, it allows them to explore an area they could pursue, Paisley said. If it wasnt an area of interest before, she said, the field trip exposes them to UNMC and neurology for the future.

Visit link:
Neurology residents offering virtual field trip into the brain - University of Nebraska Medical Center

Roche, Ascidian to develop gene therapies for neurological diseases – LabPulse

Roche has announced a research collaboration and licensing agreement with biotech firm Ascidian Therapeutics to develop gene therapies for neurological diseases.

According to the terms of their agreement, Roche will pay Ascidian $42 million upfront for exclusive, target-specific rights to use Ascidian's RNA exon-editing technology to develop therapeutics for undisclosed neurological diseases, the firms said in a statement. Furthermore, Roche will pay Ascidian up to $1.8 billion in total as research, clinical, and commercial milestones are reached. Ascidian is also eligible to receive royalties on commercial sales worldwide for any therapies that are developed under the collaboration.

Under their arrangement, Ascidian will be responsible for conducting discovery and certain preclinical activities in collaboration with Roche, and Roche will be responsible for certain other preclinical activities, as well as further clinical development, manufacturing, and commercialization, Ascidian said. While Roche will have exclusive rights to the technology for the targeted diseases, Ascidian can pursue other disease targets outside of its agreement with Roche.

Boston-based Ascidian's exon-editing technology is designed to correct the RNA produced by damaged exons, the regions of DNA containing the blueprints to make proteins. Correcting the RNA produced by damaged exons greatly mitigates the risks associated with direct DNA editing and gene replacement, such as off-target edits, Ascidian said.

See more here:
Roche, Ascidian to develop gene therapies for neurological diseases - LabPulse

University of Colorado Anschutz Medical Campus Receives $2 Million Gift from the Cline Dion Foundation to Advance … – PR Newswire

The investment will fund the Celine Dion Foundation Endowed Chair in Autoimmune Neurology at CU Anschutz

AURORA,Colo., June 18, 2024 /PRNewswire/ -- TheUniversity of Colorado Anschutz Medical Campus announced the creation of the Celine Dion Foundation Endowed Chair in Autoimmune Neurology, made possible by a $2 million philanthropic investment from the Celine Dion Foundation.

The investment will fund initiatives to advance research inautoimmune neurological disorders, such as stiff person syndrome (SPS), and support Amanda Piquet, MD, associate professor ofneurologyat theUniversity of Colorado School of Medicine, who has been named the inaugural chairholder. Piquet specializes in diagnosing, treating and advancing research for SPS, a rare, chronic and progressive autoimmune neurologic disease characterized by muscle stiffness, painful spasms and difficulty walking.

Piquet is also the director of theAutoimmune Neurology Program at CU Anschutz, where the program's mission is to provide the best neurological care and improve the well-being of patients with an autoimmune neurological disorder.

Celine Dion, who has been deeply committed to advancing healthcare for all, was diagnosed with SPS in 2022 and is an advocate forsupporting all who have been affected by the disease. Dion is being treated for SPS by Piquet at UCHealth University of Colorado Hospital on the CU Anschutz Medical Campus.

The disease currently has no cure but can be managed with symptomatic and immune therapies to make quality of life better.

This gift will help boost this field of study and expedite research discoveries, ensuring that individuals receive the most informed treatments as they become available. To enable this vision, this investment will support the following key priorities:

"SPS and other rare autoimmune neurological disorders can be difficult to diagnose and treat because they often affect individuals differently. This generous gift from the Celine Dion Foundation and the overall increased awareness for SPS will change the future of not only diagnosing the disease but will catapult research efforts to explore new approaches of treatment," said Piquet.

The $2 million investment will be provided to the campus over the next five years and allow Piquet to build upon her current success treating patients with rareautoimmune neurological disorders.

About the University of ColoradoAnschutz Medical CampusThe University of Colorado Anschutz Medical Campusis a world-class medical destination at the forefront of transformative science, medicine, educationand patient care. The campusencompassesthe University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independenthospitals-UCHealth University of Colorado HospitalandChildren's Hospital Coloradowhich see more than 2 million adult and pediatric patient visits yearly. Innovative, interconnected and highly collaborative, the University of Colorado Anschutz Medical Campusdelivers life-changingtreatments, patient care and professional training and conducts world-renowned research fueled by $705 million in research grants.For more information, visitwww.cuanschutz.edu.

Contact: Julia Milzer, University of Colorado Anschutz Medical Campus, 303-725-0733,[emailprotected]

Find the latestUniversity of Colorado Anschutz Medical Campus news here.

SOURCE University of Colorado Anschutz Medical Campus

Read more:
University of Colorado Anschutz Medical Campus Receives $2 Million Gift from the Cline Dion Foundation to Advance ... - PR Newswire

Switching From S1P-Modulating Therapies to Other DMTs – Neurology Live

At the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, NeurologyLive sat down with MS expert Donald Negroski, MD, to discuss several of the top presentations and data on treatment switches and aging in MS. Negroski provided an overview of various presentations, offering his clinical perspective and how findings may impact care going forward.

In this segment, Negroski provided commentary on a retrospective analysis highlighting the reasons for switching from sphingosine 1-phosphate (S1P)-modulating agents to ozanimod (Zeposia; BMS), another FDA-approved disease-modifying therapy. In addition, he spoke on the financial toll some patients face when choosing between approved therapies.

Transcript edited below for clarity.

Donald Negroski, MD: In the abstract, they (investigators) asked healthcare providers why patients switched from the various S1Ps to ozanimod, and the major driver was actually copay assistance and some financial issues with lack of copay as well as tolerability less so. The take-home message is that copay assistance and financial burden on patients is starting to drive treatment decisions, which is something unusual. In the past, neurologists have seemed to think thatand rightly sothey know who should go on what particular drugs and some of these recent abstracts suggest that there's other drivers, more from a financial standpoint.

Read more here:
Switching From S1P-Modulating Therapies to Other DMTs - Neurology Live

New study suggests cancer drug could be used to target protein connection that spurs Parkinson’s disease – EurekAlert

image:

Neurons express Aplp1 (in white), a key protein that allows brain cells to absorb Parkinsons-disease causing alpha-synuclein.

Credit: Yasuyoshi Kimura, Ph.D.

FOR IMMEDIATE RELEASE

In studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the spread of Parkinsons disease-causing alpha-synuclein.

The findings, published May 31 in Nature Communications, reveal how Aplp1 connects with Lag3, another cell surface receptor, in a key part of a process that helps spread harmful alpha-synuclein proteins to brain cells. Those protein buildups are hallmarks of Parkinsons disease.

Notably, the researchers say, Lag3 is already the target of a combination cancer drug approved by the U.S. Food and Drug Administration (FDA) that uses antibodies to teach the human immune system what to seek and destroy.

Now that we know how Aplp1 and Lag3 interact, we have a new way of understanding how alpha-synuclein contributes to the disease progression of Parkinsons disease, says Xiaobo Mao, Ph.D., associate professor of neurology at the Johns Hopkins University School of Medicine and a member of the Institute for Cell Engineering. Our findings also suggest that targeting this interaction with drugs could significantly slow the progression of Parkinsons disease and other neurodegenerative diseases.

Mao co-led the research along with Ted Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases at the Johns Hopkins University School of Medicine and director of the Johns Hopkins Institute for Cell Engineering, Valina Dawson, Ph.D. and Hanseok Ko, Ph.D., professors of neurology at the school of medicine and members of the Institute for Cell Engineering.

Long-standing studies have shown that by clumping together and forming protein deposits, misfolded alpha-synuclein proteins journey from brain cell to brain cell, killing those responsible for producing a neurotransmitter called dopamine, and causing Parkinsons disease to progress through a type of programmed cell death that Johns Hopkins researchers have identified. The process, parthanatos (from the Greek word for death), leads to impairments in movement, emotional regulation and thinking.

Aplp1s bond with Lag3 on the cells surface enables healthy brain cells to absorb traveling clumps of alpha-synuclein, leading to cell death, the researchers say.

In mouse studies published in 2016 and 2021, Mao and Dawsons team identified Lag3s role in binding with alpha-synuclein proteins, causing Parkinsons disease to spread. However, those studies indicated that another protein was partially responsible for the cells absorption of misfolded alpha-synuclein.

Our work previously demonstrated that Lag3 wasnt the only cell surface protein that helped neurons absorb alpha-synuclein, so we turned to Aplp1 in our most recent experiments, says Valina Dawson.

To determine whether Aplp1 indeed contributed to the spread of harmful alpha-synuclein proteins, researchers used a line of genetically engineered mice lacking either Aplp1 or Lag3 or both Aplp1 and Lag3. In mice without Aplp1 and Lag3, cell absorption of the harmful alpha-synuclein protein dropped by 90%. After injecting mice with the Lag3 antibody, they found that this drug also blocks the interaction of Aplp1 and Lag3, meaning healthy brain cells could no longer absorb disease-causing alpha-synuclein clumps.

The researchers say the Lag3 antibody nivolumab/relatlimab, a drug FDA approved in 2022 for cancer treatment, could play a role in preventing cells from absorbing alpha-synuclein.

The anti-Lag3 antibody was successful in preventing further spread of alpha-synuclein seeds in the mouse models and exhibited better efficacy than Lag3-depletion because of Aplp1s close association with Lag3, Ted Dawson says.

This research has potential applications in treating other neurodegenerative conditions that have no cures, Mao says. In Alzheimers disease, which is associated with symptoms of memory loss, mood instability and muscle problems, tau proteins become misfolded and clump together in neurons at high levels, worsening the condition. In Alzheimers research, Mao says scientists could try to target Lag3 which also binds with the dementia-related tau protein with the same antibody.

With the success of using the Lag3 antibody in mice, Ted Dawson says the next steps would be to conduct anti-Lag3 antibody trials in mice with Parkinsons disease and Alzheimers disease. The Johns Hopkins researchers are also looking into how they could prevent unhealthy cells from releasing disease-causing alpha-synuclein in the first place.

Other researchers on this study are Hao Gu, Donghoon Kim, Yasuyoshi Kimura, Ning Wang, Enquan Xu, Ramhari Kumbhar, Xiaotian Ming, Haibo Wang, Chan Chen, Shengnan Zhang, Chunyu Jia, Yuqing Liu, Hetao Bian, Senthilkumar Karuppagounder, Fatih Akkentli, Qi Chen, Longgang Jia, Heehong Hwang, Su Hyun Lee, Xiyu Ke, Michael Chang, Amanda Li, Jun Yang, Cyrus Rastegar, Manjari Sriparna, Preston Ge, Saurav Brahmachari, Sangjune Kim, Shu Zhang, Haiqing Liu, Sin Ho Kweon, Mingyao Ying and Han Seok Ko from Johns Hopkins; Yasushi Shimoda from the Nagaoka University of Technology; Martina Saar and Ulrike Muller from Heidelberg University; Creg Workman and Dario Vignali of the University of Pittsburgh School of Medicine and Cong Liu of the Chinese Academy of Sciences.

This work was supported by grants from the National Institutes of Health (R01NS107318, R01AG073291, R01AG071820, 1135 RF1NS125592, K01AG056841, R21NS125559, R01NS107404, P01AI108545, R01AI144422), the Parkinsons Foundation, the Maryland Stem Cell Research Foundation, the American Parkinson Disease Association, the Uehara Memorial Foundation, the JPB Foundation, the Adrienne Helis Malvin Medical Research Foundation, and the Parkinsons Disease Foundation.

DOI: 10.1038/s41467-024-49016-3

Nature Communications

Originally posted here:
New study suggests cancer drug could be used to target protein connection that spurs Parkinson's disease - EurekAlert

Neurology Devices Market Size 2024 Analysis by Market Dynamics, Industrial Trends, Developments and Forecast till … – openPR

Latest Report, titled "Neurology Devices Market" Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.

The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The keyword market has been expanding significantly in recent years, driven by various key factors like increased demand for its products, expanding customer base, and technological advancements. This report provides a comprehensive analysis of the Neurology Devices market, including market size, trends, drivers and constraints, competitive aspects, and prospects for future growth.

The report sheds light on the competitive landscape, segmentation, geographical expansion, revenue, production, and consumption growth of the Neurology Devices market. The keyword Market Size, Growth Analysis, Industry Trend, and Forecast provides details of the factors influencing the business scope. This report provides future products, joint ventures, marketing strategy, developments, mergers and acquisitions, marketing, promotions, revenue, import, export, CAGR values, the industry as a whole, and the particular competitors faced are also studied in the large-scale market.

Sample Pages of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/3889

Key Players Covered In This Report:

B. Braun Melsungen AG Boston Scientific Corporation BIONIK Laboratories Corp. Integra LifeSciences Holdings Corporation Johnson and Johnson Magstim Co Ltd. Braintale SAS Medtronic Abbott Zimmer Biomet Stryker Corporation Helius Medical Technologies Inc. Avanos Medical Inc. W.L. Gore & Associates Inc. HeadsafeIP Pty Ltd. Cerus Endovascular Ltd. Cyberonics Inc

This Report includes a company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The data points provided are only related to the company's focus related to Neurology Devices markets. Leading global Neurology Devices market players and manufacturers are studied to give a brief idea about competitions.

Market Segmentation:

By Device Type: CSF Management devices(CSF Shunt Devices, CSF Drainage Devices)Interventional Neurology Devices(Neuro Thromobectomy, Cerebral Balloon Angioplasty & Stents,Aneurysm Coiling, Support Devices)Neuro-surgery Devices(Neuro-endoscopes, Sterotactic- Systems, Ultrasonic- Aspirators, Aneurysm Clips) Neuro-stimulation Devices(Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation,Gastric Nerve Stimulation) By End User: Hospitals, Ambulatory surgery centers, Others

Overview and Scope of the Report:

This report is centred around the Neurology Devices in the worldwide market, with a specific focus on North America, Europe, Asia-Pacific, South America, Middle East, and Africa. The report classifies the market by manufacturers, regions, type, and application. It presents a comprehensive view of the current market situation, encompassing historical and projected market size in terms of value and volume. Additionally, the report covers technological advancements and considers macroeconomic and governing factors influencing the market.

Key Opportunities:

The report examines the key opportunities in the Neurology Devices Market and identifies the factors that are driving and will continue to drive the industry's growth. It takes into account past growth patterns, growth drivers, as well as current and future trends.

Buy-Now and Get Up to 25% Discount @ https://www.coherentmarketinsights.com/insight/buy-now/3889

Highlights of Our Report:

Extensive Market Analysis: A deep dive into the manufacturing capabilities, production volumes, and technological innovations within the Neurology Devices Market.

Corporate Insights: An in-depth review of company profiles, spotlighting major players and their strategic manoeuvres in the market's competitive arena.

Consumption Trends: A detailed analysis of consumption patterns, offering insight into current demand dynamics and consumer preferences.

Segmentation Details: An exhaustive breakdown of end-user segments, depicting the market's spread across various applications and industries.

Pricing Evaluation: A study of pricing structures and the elements influencing market pricing strategies.

Future Outlook: Predictive insights into market trends, growth prospects, and potential challenges ahead.

Why Should You Obtain This Report?

Statistical Advantage: Gain access to vital historical data and projections for the Neurology Devices Market, arming you with key statistics.

Competitive Landscape Mapping: Discover and analyze the roles of market players, providing a panoramic view of the competitive scene.

Insight into Demand Dynamics: Obtain comprehensive information on demand characteristics, uncovering market consumption trends and growth avenues.

Identification of Market Opportunities: Astutely recognize market potential, aiding stakeholders in making informed strategic decisions.

Acquiring this report ensures you are equipped with the most current and trustworthy data, sharpening your market strategies and securing a well-informed stance in the complex domain of the Neurology Devices industry. Each report is meticulously prepared, guaranteeing that our clients receive the critical intelligence needed to excel in this evolving market.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/3889

Questions Answered by the Report:

(1) Which are the dominant players of the Neurology Devices Market? (2) What will be the size of the Neurology Devices Market in the coming years? (3) Which segment will lead the Neurology Devices Market? (4) How will the market development trends change in the next five years? (5) What is the nature of the competitive landscape of the Neurology Devices Market? (6) What are the go-to strategies adopted in the Neurology Devices Market?

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

Contact Us: Mr. Shah Coherent Market Insights Pvt. Ltd, U.S.: +1-206-701-6702 U.K.: +44-020-8133-4027 AUS: +61-2-4786-0457 INDIA: +91-848-285-0837 Email: sales@coherentmarketinsights.com

:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.

See original here:
Neurology Devices Market Size 2024 Analysis by Market Dynamics, Industrial Trends, Developments and Forecast till ... - openPR

Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases – Pharmaceutical Technology Magazine

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.

Ascidian Therapeutics, a biotechnology company developing treatments by rewriting RNA, announced on June 18, 2024 that it has signed a licensing agreement with Roche to collaborate on the discovery and development of RNA exon editing therapeutics to treat neurological diseases (1). The collaboration will combine RNA exon editors with Roches next-generation central nervous system (CNS) delivery capabilities. Ascidian enables precise post-transcriptional editing of genes by editing exons at the RNA level.

As part of the agreement, Ascidian will receive an initial payment of $42 million with up to $1.8 billion in research, clinical, and commercial milestone payments, including commercial royalties. The partnership will allow Ascidian to create internal and collaborative programs within the neurology area. Roche will receive exclusive, target-specific rights to Ascidians RNA exon editing technology and will perform certain preclinical activities. Roche will also be responsible for further clinical development, manufacturing, and commercialization.

Roche is known and respected worldwide for their expertise in complex neurological diseases, and I am proud of the scientific rigor and quality of the work done at Ascidian that has led to this partnership, Michael Ehlers, MD, PhD, president and chief executive officer of Ascidian Therapeutics, said in a press release. The potential of treating disease by large-scale exon editing of RNA is vast. We look forward to working with the Roche team to develop first-in-class RNA exon editing medicines for multiple neurological diseases, with a mission and passion to relieve suffering and improve lives.

Our partnership with Ascidian is an opportunity to harness advanced RNA exon editing technology, which has the potential to deliver transformative one-time therapeutics by editing multiple whole exons at the RNA level with a single treatment, James Sabry, MD, PhD, global head of Pharma Partnering at Roche, said in the release.

In May 2024, Ascidian presented preclinical data that enabled the clearance of an investigational new drug (IND) application through Phase I/II testing for its RNA exon editor, ACDN-01, at the American Society of Gene & Cell Therapy (ASGCT) annual meeting in Baltimore, Md. FDA granted ACDN-01 Rare Pediatric Disease Designation as well as Fast Track Designation.

ACDN-01 is the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease, and we look forward to sharing the preclinical data that led to its IND clearance, along with the plans for the first-in-human trial, said Ehlers in a press release (2). ACDN-01 is designed to overcome challenges that have long kept Stargardt disease out of reach and to provide persistent therapeutic benefit with one dose. Our progress with ACDN-01 speaks to its therapeutic potential in Stargardt disease and the broader promise of our RNA exon editing platform to significantly expand the possibilities of RNA medicines.

More here:
Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases - Pharmaceutical Technology Magazine